Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 39.31 | 39.31 | 39.31 | 37.70 | 37.70 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 4,374.98 | 5,251.03 | 5,214.93 | 3,308.32 | 2,674.71 |
| Loan funds | |||||
| Secured loans | 635.07 | 629.99 | 199.91 | 1,687.03 | 859.28 |
| Unsecured loans | - | - | - | - | - |
| Total | 5,049.36 | 5,920.33 | 5,454.15 | 5,033.05 | 3,571.69 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 3,441.28 | 2,625.08 | 2,098.10 | 1,761.67 | 1,435.07 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 1,063.83 | 853.98 | 636.92 | 485.21 | 349.64 |
| Net block | 2,377.45 | 1,771.10 | 1,461.18 | 1,276.46 | 1,085.43 |
| Capital work-in-progress | 601.28 | 2,304.23 | 1,927.63 | 1,569.98 | 1,106.89 |
| Investments | 229.27 | 219.36 | 1,165.22 | 833.25 | 506.39 |
| Net current assets | |||||
| Current assets, loans & advances | 2,922.42 | 2,779.35 | 2,222.15 | 2,199.08 | 1,850.32 |
| Less : current liabilities & provisions | 1,081.06 | 1,153.71 | 1,322.03 | 845.72 | 977.34 |
| Total net current assets | 1,841.36 | 1,625.64 | 900.12 | 1,353.36 | 872.98 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 5,049.36 | 5,920.33 | 5,454.15 | 5,033.05 | 3,571.69 |
| Notes: | |||||
| Book value of unquoted investments | 229.27 | 219.36 | 978.25 | 833.25 | 506.39 |
| Market value of quoted investments | - | - | - | - | - |
| Contingent liabilities | 326.18 | 228.15 | 327.06 | 455.59 | 409.05 |
| Number of equity sharesoutstanding (Lacs) | 1965.63 | 1965.63 | 1965.63 | 1885.16 | 1885.16 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis